title: Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.
abstract: A novel series of anilinopyrazoles has been designed based on the X-ray crystal structure analysis. Most compounds from this series not only show sub-nanomolar IC(50) values for CDK2, but also demonstrate almost 1000-fold selectivity to other kinases including CDK1.
authors.affiliation: GlaxoSmithKline K. K. Tsukuba Research Laboratories, 43 Wadai Tsukuba, Ibaraki 300-4247, Japan. jt21064@gsk.com
authors.forename: Jun
authors.initials: J
authors.lastname: Tang
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Shewchuk
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Sato
authors.forename: Masaichi
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Washio
authors.forename: Naohiko
authors.initials: N
authors.lastname: Nishigaki
mesh_terms: D001665:Binding Sites; D042846:CDC2-CDC28 Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D018360:Crystallography, X-Ray; D051357:Cyclin-Dependent Kinase 2; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D006801:Humans; D020128:Inhibitory Concentration 50; D008958:Models, Molecular; D011485:Protein Binding; D011720:Pyrazoles / Q000138:chemical synthesis* / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D011720:Pyrazoles; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2